Fig. 1.
Fig. 1. Lethal effect of IL-18 with IL-2 on normal but not IL-18Rα–deficient mice. / (A) Juvenile C57BL/6 (B6) mice (n = 5 to 10 per group) were treated daily with various doses of IL-18 (0.04 to 2 μg). (B) B6 mice (n = 5 to 10 per group) were treated daily with various doses of IL-2 (10 000 to 1 Mil IU). (C) B6 mice (n = 10 per group) were treated daily with various doses of IL-18 (0.04 to 2 μg) plus IL-2 (50 000 IU). (D) B6 mice (n = 10 per group) were treated daily with various doses of IL-2 (1000 to 100 000 IU) plus IL-18 (0.5 μg). (E) Balb/c mice (n = 10 per group) were treated daily with various doses of IL-18 (0.04 to 2 μg) plus IL-2 (50 000 IU). (F) IL-18Rα−/−, 129, B6 × 129, and B6 (n = 5 to 10 per group) mice were treated daily with IL-18 (1 μg) plus IL-2 (50 000 IU) for 28 days.

Lethal effect of IL-18 with IL-2 on normal but not IL-18Rα–deficient mice.

(A) Juvenile C57BL/6 (B6) mice (n = 5 to 10 per group) were treated daily with various doses of IL-18 (0.04 to 2 μg). (B) B6 mice (n = 5 to 10 per group) were treated daily with various doses of IL-2 (10 000 to 1 Mil IU). (C) B6 mice (n = 10 per group) were treated daily with various doses of IL-18 (0.04 to 2 μg) plus IL-2 (50 000 IU). (D) B6 mice (n = 10 per group) were treated daily with various doses of IL-2 (1000 to 100 000 IU) plus IL-18 (0.5 μg). (E) Balb/c mice (n = 10 per group) were treated daily with various doses of IL-18 (0.04 to 2 μg) plus IL-2 (50 000 IU). (F) IL-18Rα−/−, 129, B6 × 129, and B6 (n = 5 to 10 per group) mice were treated daily with IL-18 (1 μg) plus IL-2 (50 000 IU) for 28 days.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal